1-(5-氯戊基)吲哚 | 61205-55-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-(5-氯戊基)吲哚
• 英文名称: 1-(5-chloropentyl)-1H-indole
• 英文别名: N-(5-chloropentyl)indole；1-(5-chloropentyl)indole
• CAS: 61205-55-8
• 化学式: C₁₃H₁₆ClN
• 分子量: 221.73
• InChiKey: HKMYTNVURQUCSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-(5-氯戊基)吲哚 、 6-氟-3-(哌啶-4-基)苯并[D]异恶唑 在 N,N-二异丙基乙胺 、 potassium iodide 、 盐酸 作用下， 以 乙腈 、 乙醇 、 乙酸乙酯 为溶剂， 反应 15.0h， 以63.8%的产率得到3-(1-(5-(1H-indol-1-yl)pentyl)piperidin-4-yl)-6-fluorobenzo[d]isoxazole hydrochloride
  参考文献：
  名称：

  BENZISOXAZOLE PIPERIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE DERIVATIVES AND THEIR USE

  摘要：

  本发明涉及一种苯并异噁唑基哌啶衍生物，其具有以下通式，其盐或水合物，其中R，X，Y，R'和T在规范中定义。这样的化合物具有调节血清素系统的作用，例如对5-HT2A的拮抗作用和对5-HT再摄取的抑制作用。这些化合物具有良好的镇痛和镇静活性，毒性和副作用较轻。本发明还涉及包含该衍生物的组合物及其使用。

  公开号：

  US20110306638A1
• 作为产物：
  描述：

  1-phenylspiro[2a,7b-dihydroazeto[3,2-b]indol-3-ium-3,1'-azinan-1-ium]-2-one;chloride 以95%的产率得到
  参考文献：
  名称：

  BENTLEY R. L.; SUSCHITZKY H., J. CHEM. SOC. PERKIN TRANS., 1976, PART 1, NO 16, 1725-1734

  摘要：

  DOI：

文献信息

• Substituted anilinic piperidines as MCH selective antagonists
  申请人：Marzabadi R. Mohammad

  公开号：US20070043080A1

  公开（公告）日：2007-02-22

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

  本发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供了一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供了一种由本发明化合物的治疗有效量和药学上可接受的载体组成的药物组合物。本发明还提供了一种制备药物组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。
• NOVEL BENZAMIDE DERIVATIVES
  申请人：Kim Soon-Hoe

  公开号：US20130085160A1

  公开（公告）日：2013-04-04

  The present invention provides a novel benzamide derivative or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a 5-HT 4 receptor agonist containing the same as an active ingredient. Benzamide derivatives of the present invention have a superior affinity for 5-HT 4 receptors, a capability to reduce a gastric emptying time and a low toxicity, and consequently are therapeutically effective for the treatment of a variety of diseases associated with 5 -HT 4 receptors.

  本发明提供了一种新型苯甲酰胺衍生物或其药物可接受的盐，其制备方法，以及含有其作为活性成分的5-HT4受体激动剂。本发明的苯甲酰胺衍生物具有优异的5-HT4受体亲和力，能够缩短胃排空时间和低毒性，因此在治疗与5-HT4受体相关的多种疾病方面具有治疗效果。
• Discovery of novel 4‐methylpiperidinyl benzamide derivatives as <scp> 5‐HT ₄ </scp> receptor agonist for the treatment of gastrointestinal disorders
  作者：Sunho Choi、Min Jung Lee、Kwang‐Hyun Ahn

  DOI：10.1002/bkcs.12667

  日期：——

  Novel 4-methypiperidinyl benzamide derivatives were synthesized and evaluated for in vitro and in vivo prokinetic activities. In these derivatives, 3-methoxypiperidine moiety of norcisapride, a pharmacophore of cisapride and DA-6650, were replaced to 4-methylpiperidinyl moiety without chiral center. Among these derivatives, Compound 28b had a potent 5-HT4 receptor-binding affinity (IC50 = 0.067 μM)

  合成了新型 4-甲基哌啶基苯甲酰胺衍生物，并评估了体外和体内的促运动活性。在这些衍生物中，去甲西沙必利的 3-甲氧基哌啶部分、西沙必利的药效团和 DA-6650 被替换为没有手性中心的 4-甲基哌啶基部分。在这些衍生物中，化合物28b具有强效的 5-HT 4受体结合亲和力 (IC 50  = 0.067 μM)，并且在不抑制 CYP3A4 (IC 50  = 7.272 μM) 和阻断人类 ether-à-go-go-related 的情况下提高了安全性基因 (hERG) 通道 (IC 50  > 10 μM)。体内大鼠模型，化合物28b与对照组相比，胃排空率提高 (68.2%)，排便重量增加两倍以上。此外，它在刺激大鼠模型中显示出内脏超敏反应的缓解作用。因此，化合物28b被选为临床前候选药物，作为促动力剂，具有良好的安全性，可用于治疗胃肠道疾病。
• Indolylalkyltriphenylphosphonium Analogues Are Membrane-Depolarizing Mycobactericidal Agents
  作者：Ming Li、Samuel A. Nyantakyi、Pooja Gopal、Dinah binte Aziz、Thomas Dick、Mei-Lin Go

  DOI：10.1021/acsmedchemlett.7b00287

  日期：2017.11.9

  Agents that selectively target the mycobacterial membrane could potentially shorten treatment time for tuberculosis, reduce relapse, and curtail emergence of resistant strains. The lipophilicity and extensive charge-delocalized state of the triphenylphosphonium cation strongly favor accumulation within bacterial membranes. Here, we explored the antimycobacterial activities and membrane-targeting properties of indolylalkyltriphenylphosphonium analogues. The most active analogues preferentially inhibited growth of Mycobacterium tuberculosis H37Rv (MIC50 2-4 mu M) and were bactericidal against Mycobacterium bovis BCG (MBC99 3 mu M). In spite of their propensity to accumulate within membranes, we found no evidence that these compounds permeabilized mycobacterial membranes or induced cell-envelope stress. Our investigations indicated that their bacterical effects stem from sustained depolarization of mycobacterial membranes and ensuing disruptive effects on electron transfer and cell division.
• Nickel-Catalyzed C(sp³)–Sb Coupling of Chlorostibines with Unactivated Alkyl Chlorides and In Vitro Anticancer Activity of Products
  作者：Liyuan Le、Mingming Yin、Huifan Zeng、Wuxing Xie、Wenjun Zhou、Yi Chen、Biquan Xiong、Shuang-Feng Yin、Nobuaki Kambe、Renhua Qiu

  DOI：10.1021/acs.orglett.3c04008

  日期：2024.1.12